title: Ganoderma lucidum Polysaccharides Induce Macrophage-Like Differentiation in Human Leukemia THP-1 Cells via Caspase and p53 Activation.
abstract: Differentiation therapy by induction of tumor cells is an important method in the treatment of hematological cancers such as leukemia. Tumor cell differentiation ends cancer cells' immortality, thus stopping cell growth and proliferation. In our previous study, we found that fucose-containing polysaccharide fraction F3 extracted from Ganoderma lucidum can bring about cytokine secretion and cell death in human leukemia THP-1 cells. This prompted us to further investigate on how F3 induces the differentiation in human leukemia cells. We integrated time-course microarray analysis and network modeling to study the F3-induced effects on THP-1 cells. In addition, we determined the differentiation effect using Liu's staining, nitroblue tetrazolium (NBT) reduction assay, flow cytometer, western blotting and Q-PCR. We also examined the modulation and regulation by F3 during the differentiation process. Dynamic gene expression profiles showed that cell differentiation was induced in F3-treated THP-1 cells. Furthermore, F3-treated THP-1 cells exhibited enhanced macrophage differentiation, as demonstrated by changes in cell adherence, cell cycle arrest, NBT reduction and expression of differentiation markers including CD11b, CD14, CD68, matrix metalloproteinase-9 and myeloperoxidase. In addition, caspase cleavage and p53 activation were found to be significantly enhanced in F3-treated THP-1 cells. We unraveled the role of caspases and p53 in F3-induced THP-1 cells differentiation into macrophages. Our results provide a molecular explanation for the differentiation effect of F3 on human leukemia THP-1 cells and offer a prospect for a potential leukemia differentiation therapy.
authors.affiliation: Institute of Molecular and Cellular Biology, Department of Life Science, Graduate Institute of Biomedical Electronics and Bioinformatics, Center for Systems Biology and Bioinformatics, Institute of Biochemical Sciences, National Taiwan University, Taiwan.
authors.forename: Jia-Wei
authors.initials: JW
authors.lastname: Hsu
authors.forename: Hsuan-Cheng
authors.initials: HC
authors.lastname: Huang
authors.forename: Shui-Tein
authors.initials: ST
authors.lastname: Chen
authors.forename: Chi-Huey
authors.initials: CH
authors.lastname: Wong
authors.forename: Hsueh-Fen
authors.initials: HF
authors.lastname: Juan
references.citation: Cytokine Growth Factor Rev. 2000 Dec;11(4):303-20
references.pmid: 10959078
references.citation: Cancer Biol Ther. 2002 Nov-Dec;1(6):614-20
references.pmid: 12642682
references.citation: J Immunol. 2004 Nov 15;173(10):5989-99
references.pmid: 15528333
references.citation: Leukemia. 1998 Dec;12(12):1944-50
references.pmid: 9844924
references.citation: Clin Exp Immunol. 1990 Mar;79(3):448-53
references.pmid: 2317949
references.citation: Biotechnol Annu Rev. 2007;13:265-301
references.pmid: 17875480
references.citation: J Biol Chem. 2006 Aug 25;281(34):24111-23
references.pmid: 16798741
references.citation: J Biol Chem. 2003 Dec 19;278(51):51340-6
references.pmid: 14534304
references.citation: Gen Pharmacol. 1999 Jan;32(1):143-54
references.pmid: 9888267
references.citation: BMC Genomics. 2007 Nov 09;8:411
references.pmid: 17996095
references.citation: N Engl J Med. 1999 Sep 30;341(14):1051-62
references.pmid: 10502596
references.citation: Phytochemistry. 2006 Sep;67(18):1985-2001
references.pmid: 16905165
references.citation: Pharmacol Ther. 1997 Oct-Dec;76(1-3):141-9
references.pmid: 9535176
references.citation: Oncogene. 2000 May 15;19(21):2548-56
references.pmid: 10851053
references.citation: Bioorg Med Chem. 2004 Nov 1;12(21):5595-601
references.pmid: 15465337
references.citation: Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71
references.pmid: 17317642
references.citation: Leukemia. 2002 Jun;16(6):1143-53
references.pmid: 12040446
references.citation: Leuk Lymphoma. 2003 Oct;44(10):1641-50
references.pmid: 14692514
references.citation: Cell Death Differ. 2007 Jan;14(1):44-55
references.pmid: 17053807
references.citation: Nat Rev Cancer. 2003 Feb;3(2):89-101
references.pmid: 12563308
references.citation: Blood. 2002 Oct 1;100(7):2421-9
references.pmid: 12239152
references.citation: Nat Rev Cancer. 2007 Mar;7(3):165-8
references.pmid: 17332760
references.citation: Leukemia. 2006 Jun;20(6):941-51
references.pmid: 16617325
references.citation: Curr Drug Targets. 2007 Jun;8(6):685-701
references.pmid: 17584025
references.citation: Nutr Cancer. 2005;53(1):11-7
references.pmid: 16351502
references.citation: J Leukoc Biol. 2007 Sep;82(3):710-20
references.pmid: 17595377
references.citation: Leukemia. 2008 Aug;22(8):1624-7
references.pmid: 18305561
references.citation: Stem Cell Rev. 2005;1(3):197-205
references.pmid: 17142856
references.citation: Blood. 2002 Dec 15;100(13):4446-53
references.pmid: 12393560
references.citation: Cell Death Differ. 2004 Apr;11(4):458-67
references.pmid: 14713961
references.citation: Leuk Res. 1999 Mar;23(3):235-7
references.pmid: 10071074
references.citation: J Leukoc Biol. 2007 Jun;81(6):1568-76
references.pmid: 17369494
references.citation: Cell Signal. 2004 Mar;16(3):365-74
references.pmid: 14687666